Monkeypox Testing Market Size & Growth Forecast 2027–2036, By Segments (Technology Type, End-use Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Monkeypox Testing Market size was over USD 2.26 million in 2026 and is likely to grow at a 4.09% CAGR between 2027 and 2036, exceeding USD 3.37 million by 2036. The industry revenue for 2027 is calculated at USD 2.34 million.
Get more details on this report
Request Free Sample ReportMonkeypox Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 42.45% of the market in 2026, supported by advanced diagnostic infrastructure, strong laboratory capacity, and efficient integration of disease surveillance into healthcare systems.
- Asia Pacific is projected to grow at a 5.13% CAGR, driven by expanding diagnostic access, stronger public health monitoring, and greater investment in outbreak preparedness and molecular testing capabilities.
Segment Momentum
- PCR held the largest share in 2026 due to its high diagnostic accuracy, established laboratory integration, and critical role in confirmatory testing for clinical and public health decision-making.
- LFA is the fastest-growing segment as demand rises for rapid, decentralized testing solutions that enable quicker screening and easier deployment outside traditional laboratory settings.
Market Expansion Drivers
- Government-led outbreak surveillance programs increasing diagnostic testing demand.
- Advancements in PCR-based diagnostics improving accuracy and testing scalability.
- Expansion of decentralized rapid testing infrastructure strengthening epidemic preparedness.
Leading Market Participants
- Key companies in the monkeypox testing market include Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Netherlands), Quest Diagnostics Incorporated (United States), Laboratory Corporation of America Holdings (United States), Becton, Dickinson and Company (United States), Mayo Clinic Laboratories (United States), Aegis Sciences Corporation (United States), Chembio Diagnostics, Inc. (United States), Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd (Switzerland).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.26 million
- 2027 Estimated Market Size: USD 2.34 million.
- Projected Market Size: USD 3.37 million by 2036
- Growth Forecast: 4.09% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Polymerase Chain Reaction (PCR) (Technology Type) | Hospitals & Clinics (End-use Type)
- Emerging Opportunity Segment: Lateral Flow Assay (LFA) (Technology Type) | Diagnostic Laboratories (End-use Type)
Market Growth Drivers and Industry Trends
Government-led outbreak surveillance programs increasing diagnostic testing demand
Government-led outbreak surveillance programs will drive the monkeypox testing market growth by strengthening systematic monitoring of suspected and confirmed cases across healthcare facilities and communities. Public health authorities rely on diagnostic testing to identify infections, track transmission patterns, and support timely containment measures during outbreaks. Expanded surveillance also encourages healthcare providers to maintain greater testing readiness, particularly when symptoms overlap with other infectious diseases and laboratory confirmation is needed for appropriate case management. As surveillance networks become more coordinated, testing demand can extend beyond hospitals to public health laboratories, screening centers, and other diagnostic settings involved in outbreak monitoring.
Advancements in PCR-based diagnostics improving accuracy and testing scalability
The monkeypox testing market is benefiting from advancements in PCR-based diagnostic technologies that provide sensitive and reliable identification of viral genetic material. Improved assay design, laboratory workflows, and testing automation can support more consistent results while allowing diagnostic facilities to process samples efficiently during periods of increased demand. PCR-based methods are particularly valuable where accurate differentiation of infection is required, helping healthcare professionals and public health agencies make informed decisions regarding patient management and disease surveillance. Greater laboratory capability also supports the expansion of testing capacity across established diagnostic networks.
Expansion of decentralized rapid testing infrastructure strengthening epidemic preparedness
Expansion of decentralized rapid testing infrastructure will boost the monkeypox testing market demand by bringing diagnostic capabilities closer to communities and healthcare settings that may have limited access to centralized laboratories. Rapid testing can shorten the time between sample collection and result availability, supporting faster clinical assessment and public health responses when suspected infections emerge. Decentralized facilities can also improve testing accessibility during localized outbreaks, particularly where transportation of samples to distant laboratories may delay diagnosis. Investment in distributed diagnostic capacity further strengthens preparedness by enabling healthcare systems to activate testing resources more quickly when infectious disease activity increases.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Government-led outbreak surveillance programs increasing diagnostic testing demand | 2.00% | High | North America, Europe | Medium | Near Term |
| Advancements in PCR-based diagnostics improving accuracy and testing scalability | 1.50% | High | North America, Europe | High | Near Term |
| Expansion of decentralized rapid testing infrastructure strengthening epidemic preparedness | 1.20% | High | Global | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the monkeypox testing market at 42.45% in 2026, supported by established infectious disease surveillance systems, well-developed laboratory infrastructure, and strong public-health preparedness. The region's extensive diagnostic capabilities enable timely testing and case identification, while healthcare institutions and public-health authorities continue to prioritize rapid detection of emerging infectious diseases. Greater awareness among healthcare professionals and the availability of specialized molecular diagnostic technologies further reinforce demand for monkeypox testing across the region.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is positioned as the fastest-growing regional market, driven by expanding healthcare infrastructure, increasing investment in laboratory diagnostics, and greater emphasis on infectious disease surveillance. Improvements in access to diagnostic services across emerging healthcare systems are supporting broader testing capacity, while rising awareness of communicable disease risks is encouraging earlier clinical evaluation and diagnosis. The region's large and diverse population, combined with strengthening public-health preparedness and growing adoption of advanced diagnostic technologies, is expected to sustain momentum in monkeypox testing demand.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Network ExpansionGermany reinforces monkeypox testing through coordinated diagnostic laboratories and standardized testing protocols. Healthcare institutions across Germany emphasize accurate molecular diagnostics and efficient sample processing to strengthen infectious disease surveillance.
France 🇫🇷
Integrated Disease SurveillanceFrance supports monkeypox testing through coordinated public health laboratories and strengthened infectious disease monitoring. Healthcare authorities in France emphasize accessible diagnostics and effective reporting systems to improve outbreak management capabilities.
Italy 🇮🇹
Clinical Testing ReadinessItaly continues improving monkeypox testing availability across hospital laboratories and reference diagnostic centers. Healthcare providers in Italy prioritize dependable molecular testing and coordinated laboratory workflows to support timely clinical decision-making and public health monitoring.
Japan 🇯🇵
Diagnostic Quality StandardsJapan focuses on highly reliable monkeypox testing supported by rigorous laboratory quality requirements. Diagnostic providers in Japan prioritize validated testing methods and efficient integration with national infectious disease monitoring systems.
South Korea 🇰🇷
Rapid Response DiagnosticsSouth Korea continues enhancing monkeypox testing readiness through advanced molecular diagnostic capabilities and responsive laboratory infrastructure. Healthcare organizations in South Korea prioritize fast turnaround times and coordinated surveillance for suspected cases.
United States 🇺🇸
Public Health PreparednessThe U.S. continues strengthening monkeypox testing capacity through expanded laboratory networks and rapid molecular diagnostics. Healthcare providers in the U.S. prioritize timely case identification and scalable testing capabilities to support outbreak response efforts.
Segment Leadership and Growth Trends
Monkeypox Testing Market Share (%), by Technology Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTechnology Type Segment Analysis: Polymerase Chain Reaction (PCR) (Largest Segment) vs Lateral Flow Assay (LFA) (Fastest-Growing Segment)
The polymerase chain reaction (PCR) segment represented the largest share of the monkeypox testing market in 2026, supported by its established role in molecular detection and its ability to deliver highly sensitive identification of viral genetic material. PCR-based testing is well suited to clinical settings where reliable diagnostic confirmation is essential for patient management and infection-control decisions. Established laboratory workflows, standardized testing practices, and the ability to detect infections with high analytical precision continue to support the technology's prominent position.
The lateral flow assay (LFA) segment is expected to grow at the fastest pace, driven by demand for simpler and more accessible testing approaches that can provide rapid results. LFA-based solutions can reduce dependence on complex laboratory infrastructure, making them attractive for decentralized testing environments and situations requiring timely screening. Their ease of operation and potential for point-of-care use can improve testing accessibility, particularly where rapid preliminary assessment is important. Continued interest in convenient diagnostic formats is therefore creating favorable conditions for broader adoption of lateral flow technologies.
End-use Type Segment Analysis: Hospitals & Clinics (Largest Segment) vs Diagnostic Laboratories (Fastest-Growing Segment)
Hospitals & clinics accounted for the largest share of the monkeypox testing market in 2026, reflecting their central role in evaluating suspected infections and coordinating diagnostic and clinical care. These healthcare facilities are positioned to integrate testing with patient examination, treatment decisions, isolation procedures, and infection-control protocols. Their established diagnostic infrastructure and access to healthcare professionals make them important settings for timely testing, particularly when patients present with symptoms requiring clinical assessment.
Diagnostic laboratories are anticipated to register the fastest growth as healthcare systems increasingly rely on specialized testing facilities for molecular diagnostics and centralized sample processing. Laboratories can support efficient handling of testing workflows, standardized analytical procedures, and broader diagnostic capacity beyond individual clinical facilities. Growing demand for reliable testing services and the increasing specialization of laboratory-based diagnostics are strengthening the role of diagnostic laboratories within the testing ecosystem.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Technology Type | Polymerase Chain Reaction (PCR), Lateral Flow Assay (LFA), Others | Polymerase Chain Reaction (PCR) | Lateral Flow Assay (LFA) |
| End-use Type | Hospitals & Clinics, Diagnostic Laboratories, Others | Hospitals & Clinics | Diagnostic Laboratories |
Competitive Landscape and Market Positioning
Key companies in the monkeypox testing market:
1. Thermo Fisher Scientific Inc. (United States)
2. QIAGEN N.V. (Netherlands)
3. Quest Diagnostics Incorporated (United States)
4. Laboratory Corporation of America Holdings (United States)
5. Becton Dickinson and Company (United States)
6. Mayo Clinic Laboratories (United States)
7. Aegis Sciences Corporation (United States)
8. Chembio Diagnostics Inc. (United States)
9. Abbott Laboratories (United States)
10. F. Hoffmann-La Roche Ltd (Switzerland)
Diagnostic accuracy improvements are driving innovation in testing methodologies. Faster detection and broader accessibility are key priorities across healthcare systems. In the monkeypox testing market, reliability and rapid response capabilities remain central to development efforts.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (United States) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| Laboratory Corporation of America Holdings (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Mayo Clinic Laboratories (United States) | |||||||
| Aegis Sciences Corporation (United States) | |||||||
| Chembio Diagnostics Inc. (United States) | |||||||
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Global Health Innovative Technology Fund | Dec-25 | The Global Health Innovative Technology Fund invested JPY 70 million to advance development of a prototype mpox detection assay. The funding supports early-stage diagnostic innovation aimed at improving detection capabilities and strengthening global preparedness for mpox-related infectious disease monitoring. |
| South African Health Products Regulatory Authority | May-25 | The South African Health Products Regulatory Authority listed the first mpox in-vitro diagnostic through the WHO reliance pathway. The regulatory approval expands availability of standardized diagnostic testing within national healthcare systems, supporting improved disease surveillance and laboratory diagnostic capacity. |
| Quest Diagnostics | Sep-22 | Quest Diagnostics received U.S. FDA emergency use authorization for its lab-developed molecular diagnostic test for monkeypox infection. The approval enabled commercialization of its testing solution, expanding its infectious disease diagnostics portfolio and supporting broader laboratory-based detection capacity during outbreak conditions. |
| CerTest Biotec | Jun-22 | CerTest Biotec partnered with BD (Becton, Dickinson and Company) to develop a molecular diagnostic test for monkeypox using the BD MAX open system reagent platform. The collaboration expands access to validated diagnostic solutions and strengthens molecular testing capabilities for infectious disease detection within global laboratory networks. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Monkeypox Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Testing Purpose | Diagnostic Testing, Screening Testing, Confirmatory Testing |
| Sample Type | Lesion Swabs, Oropharyngeal Swabs, Nasopharyngeal Swabs, Blood & Serum Samples |
| Regulatory Approval Status | Fully Approved Tests, Emergency or Temporary Authorized Tests, Tests Under Regulatory Review |
Monkeypox Testing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Global Outbreak Preparedness and Testing Demand Scenarios |
|
| National Diagnostic Procurement and Tender Landscape |
|
| Emerging Multiplex and Syndromic Testing Threats |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the monkeypox testing market?
What is the forecasted size of the monkeypox testing industry?
How are government surveillance initiatives influencing demand in the monkeypox testing market?
Why is decentralized testing infrastructure becoming strategically important in the monkeypox testing market?
Why does PCR dominate monkeypox diagnostic testing?
What is driving growth in lateral flow assay (LFA) testing?
Why is North America the leading region in the monkeypox testing market?
What is driving growth in the monkeypox testing market across Asia Pacific?
Who are the leading players in the monkeypox testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization